GEN-MKT-18-7897-A
Aug 20, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
A recent study by Katy Williams (UCSF), Christie Hunter (SCIEX), and Andrew Olsen (Advaita) used the iPathwayGuide within the OneOmics cloud computing environment to help understand how placental development can go awry during certain pregnancy complications such as pre-eclampsia.
In this pilot study, the researchers studied cytotrophoblast differentiation. Cytotrophoblasts are the cells that are mainly responsible for establishing an anchor between the developing embryo and placenta with the uterine wall. The researchers compared cytotrophoblasts from the primary culture at both 2nd trimester and full term. SWATH proteomics data acquired using a SCIEX TripleTOF® 6600 System were analyzed in OneOmics using iPathwayGuide to identify differentially regulated proteins and their associated pathways, biological processes, and molecular functions. The proteomics data were then compared with RNASeq transcriptomics data acquired using an Illumina HiSeq System. Both the proteomics data and transcriptomics data were correlated using the OneOmics Platform and iPathwayGuide in the cloud. This meta-analysis allowed the researchers to discover common pathways and processes between the data sets as well as those only observed in the proteomic or transcriptomic datasets alone.
The pilot study helped to illuminate the biological significance of multiple proteins and pathways and provided an effective pipeline for taking raw data to biological answers.
See the complete study by viewing a 10 minute mini webinar. If you’d like to get a demo of the OneOmics Project, just comment below and we’ll be in touch.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network